Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Adagrasib

FDA-approved product (tablet, oral), marketed as Krazati.

Registered studies
40
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Adagrasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Adagrasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Adagrasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

    NCT05178888 · start 2022-01-20

    Registered record
    Registry ID
    NCT05178888
    Conditions
    Advanced Solid Tumor
    Interventions
    MRTX849; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-20
    Completion
    2024-12-30
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionMRTX849; Palbociclib
    PhasePhase 1
    Registry statusCompleted

  • Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

    NCT04975256 · start 2021-07-28

    Registered record
    Registry ID
    NCT04975256
    Conditions
    Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung; Malignant Neoplastic Disease
    Interventions
    MRTX849; BI 1701963
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-07-28
    Completion
    2022-11-15
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung +1 more
    InterventionMRTX849; BI 1701963
    PhasePhase 1
    Registry statusTerminated

  • Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

    NCT04793958 · start 2021-06-24

    Registered record
    Registry ID
    NCT04793958
    Conditions
    Advanced Colorectal Cancer; Metastatic Colorectal Cancer
    Interventions
    MRTX849; Cetuximab; mFOLFOX6 Regimen; FOLFIRI Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-06-24
    Completion
    2026-07-31
    Enrolment
    461

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Colorectal Cancer; Metastatic Colorectal Cancer
    InterventionMRTX849; Cetuximab; mFOLFOX6 Regimen; FOLFIRI Regimen
    PhasePhase 3
    Registry statusActive not recruiting

  • Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

    NCT04685135 · start 2021-02-23

    Registered record
    Registry ID
    NCT04685135
    Conditions
    Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
    Interventions
    MRTX849; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-02-23
    Completion
    2026-10-30
    Enrolment
    453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
    InterventionMRTX849; Docetaxel
    PhasePhase 3
    Registry statusActive not recruiting

  • Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    NCT04613596 · start 2020-12-02

    Registered record
    Registry ID
    NCT04613596
    Conditions
    Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
    Interventions
    Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-12-02
    Completion
    2029-10-31
    Enrolment
    626

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
    InterventionAdagrasib; Adagrasib; Adagrasib; Adagrasib +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

    NCT04418661 · start 2020-06-09

    Registered record
    Registry ID
    NCT04418661
    Conditions
    Metastatic Neoplasm
    Interventions
    Vociprotafib; Pembrolizumab; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-06-09
    Completion
    2024-04-04
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Neoplasm
    InterventionVociprotafib; Pembrolizumab; Adagrasib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

    NCT04330664 · start 2020-04-07

    Registered record
    Registry ID
    NCT04330664
    Conditions
    Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
    Interventions
    MRTX849; TNO155
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-04-07
    Completion
    2025-02-24
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
    InterventionMRTX849; TNO155
    PhasePhase 1
    Registry statusCompleted

  • Genetic Testing in Guiding Treatment for Patients With Brain Metastases

    NCT03994796 · start 2019-10-17

    Registered record
    Registry ID
    NCT03994796
    Conditions
    CDK Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation; PI3K Gene Mutation; ROS1 Gene Mutation; KRAS G12C Mutation
    Interventions
    Abemaciclib; PI3K Inhibitor paxalisib; Entrectinib; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-10-17
    Completion
    2028-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCDK Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation +3 more
    InterventionAbemaciclib; PI3K Inhibitor paxalisib; Entrectinib; Adagrasib
    PhasePhase 2
    Registry statusActive not recruiting

  • Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

    NCT03785249 · start 2019-01-15

    Registered record
    Registry ID
    NCT03785249
    Conditions
    Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
    Interventions
    MRTX849; Pembrolizumab; Cetuximab; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2019-01-15
    Completion
    2026-12-31
    Enrolment
    731

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
    InterventionMRTX849; Pembrolizumab; Cetuximab; Afatinib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

    NCT05162443

    Registered record
    Registry ID
    NCT05162443
    Conditions
    Advanced Cancer; Metastatic Cancer; Malignant Neoplasm
    Interventions
    adagrasib (MRTX849)
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Metastatic Cancer; Malignant Neoplasm
    Interventionadagrasib (MRTX849)
    PhaseNot recorded
    Registry statusApproved for marketing